Venkatraman Srinivasan, MD
Interventional Cardiology · Natrona Heights, PANPI 1588623953
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,500 of the $26,298 with a category attached, or 62.7%. Novartis accounts for 65.5% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2019 at $17,908 and has fallen 89.8% since, to $1,821 in 2025.
Across 267 payments — averaging $98.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$17K
- Amgen$1K
- Jenavalve Technology, Inc.$889
- Heartflow, Inc.$808
- E.r. Squibb & Sons, L.L.C.$771
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$766
- plus $5K from 28 others
Across 57 payments — averaging $3379.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$109K
- AstraZeneca$40K
- Esperion Therapeutics, Inc.$26K
- Astrazeneca UK Limited$17K
What the payments were for
- Consulting fees$8893%
- Speaking & faculty fees$16,50063%
- Food & beverage$8,67133%
- Education$2391%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 29 | $17,232 |
| Amgen | 37 | $1,039 |
| Jenavalve Technology, Inc. | 1 | $889 |
| Heartflow, Inc. | 13 | $808 |
| E.r. Squibb & Sons, L.L.C. | 40 | $771 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $766 |
| Johnson & Johnson | 25 | $657 |
| Pfizer | 20 | $473 |
| Actelion Pharmaceuticals US, Inc. | 10 | $472 |
| Abbott | 4 | $358 |
| Edwards Lifesciences | 4 | $334 |
| Shockwave Medical, Inc | 3 | $254 |
| Abiomed | 3 | $230 |
| Boehringer Ingelheim | 7 | $227 |
| Merck | 10 | $218 |
| AstraZeneca | 12 | $198 |
| Medtronic | 2 | $186 |
| Esperion Therapeutics, Inc. | 4 | $173 |
| Inari Medical, Inc. | 1 | $170 |
| Scpharmaceuticals Inc. | 6 | $132 |
| Vifor Pharma, Inc. | 3 | $122 |
| Lantheus Medical Imaging, Inc. | 1 | $102 |
| Boston Scientific | 2 | $84 |
| Alnylam Pharmaceuticals Inc. | 1 | $72 |
| Kestra Medical Technology Services, Inc. | 2 | $66 |
| Bayer | 3 | $50 |
| Chiesi USA, Inc. | 3 | $46 |
| Lexicon Pharmaceuticals, Inc. | 1 | $44 |
| Cardiovascular Systems Inc. | 2 | $26 |
| Novo Nordisk | 1 | $24 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $21 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$16,603
- Repatha$338
- FFRct$318
- SAPIEN 3 Ultra RESILIA$226
- COREVALVE EVOLUT R$173
- FLOWTRIEVER CATHETER, S$170
- CT THROMBECTOMY SYSTEM KIT$170
- HeartMate 3 Left Ventricular Dev$164
- XACT$162
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$155
- XARELTO$148
- Impella$138
- OPSUMIT$125
- Veltassa$117
- LifeVest$107
- CAMZYOS$105
- Definity$102
How this compares
$26,298 in reported general payments places this provider in the 80th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 349 | $301,478 |
| CamzyosMavacamten | 23 | $197,742 |
| EntrestoSacubitril/Valsartan | 109 | $132,707 |
| XareltoRivaroxaban | 145 | $130,777 |
| Repatha SureclickEvolocumab | 74 | $65,244 |
| JardianceEmpagliflozin | 79 | $64,909 |
| BrilintaTicagrelor | 11 | $11,057 |
| Praluent PenAlirocumab | 11 | $9,046 |
| Metoprolol Succinate | 625 | $7,607 |
| Rosuvastatin Calcium | 392 | $5,667 |
| VascepaIcosapent Ethyl | 11 | $4,047 |
| Valsartan | 128 | $3,931 |
| Ranolazine ErRanolazine | 52 | $3,410 |
| Atorvastatin Calcium | 273 | $2,489 |
| Icosapent Ethyl | 16 | $2,424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $473 | $301,478349 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $771 | $197,74223 claims |
| NovartisEntresto | $17,232 | $132,707109 claims |
| Johnson & JohnsonXarelto | $657 | $130,777145 claims |
| Boehringer IngelheimJardiance | $227 | $64,90979 claims |
| AstraZenecaBrilinta | $198 | $11,05711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Natrona Heights
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1M
- William GrayWynnewood$753K
- Jon GeorgePhiladelphia$637K
- Shailendra SinghAllentown$470K
- Sanjog KalraPhiladelphia$444K
- James HarveyChambersburg$442K
- Taisei KobayashiPhiladelphia$384K
- Antonis PratsosBroomall$377K
- Ronald FieldsNew Hope$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.